Prognostic Model of Hypertension

Hypertension Clinical Trial

— PHOP-HT  

Official title:

Prognostic Model of Hypertension

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06160921
• Other study ID #: 20190818
• Status: Recruiting
• Start date: January 1, 2020
• Est. completion date: January 1, 2030

Study information

• Verified date: March 2024
• Source: Xinjiang Medical University
• Contact: Xiang Xie, Phd
• Phone: 15099169036
• Email: xiangxie999[@]sina.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of this study was to establish a registration and monitoring system for hypertension in Xinjiang from 2020 to 2030 to obtain real information about patient basic information, patient characteristics, diagnostic test patterns, treatment options, and hospitalization outcomes (including mortality). Treatment complications, hospitalization costs, and end-of-life events (death, major adverse cardiac events, mild adverse cardiovascular events) in patients with hypertension in Xinjiang; and scientific prevention strategies aimed at effectively preventing the onset of hypertension; Guidelines in clinical practice recommend, analyze and develop effective treatment strategies to optimize management and outcomes for patients with hypertension; and create cost-effective assessment systems.

Description:

The aim of the study is to establish a platform for monitoring, clinical research and translational medicine in Xinjiang, which aims to provide a basis for future quality improvement and research, and to promote efforts to improve the prognosis of patients with hypertension, and to translate research into improved care for patients, thereby reducing Morbidity and mortality associated with hypertension.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50000
• Est. completion date: January 1, 2030
• Est. primary completion date: January 1, 2030
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• A patient diagnosed with primary hypertension who was admitted to the First Affiliated Hospital of Xinjiang Medical University

Exclusion Criteria:

• Patients with secondary hypertension, patients with liver and kidney dysfunction,

• patients with mental disorders, and patients who are unwilling to participate in this trial

Related Conditions & MeSH terms

• Hypertension

Intervention

Other:
• Standard therapy
Individualized blood pressure reduction program

Locations

Country	Name	City	State
China	The First Affiliated Hospital of Xinjiang Medicial University	Ürümqi	Xinjiang

Sponsors (1)

Lead Sponsor	Collaborator
Xinjiang Medical University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Resistant hypertension		10 years of follow-up Resistant hypertension occurred during this period
Primary	Death (all-cause mortality, mortality from hypertension complications)		10 years of follow-up deaths occurred during this period
Secondary	Major adverse cardiovascular events		10 years of follow-up deaths occurred during this period